Mouse Anti-Human HSP90 alpha/beta Monoclonal Antibody (CBP3889)

Product Overview

Description

Hsp90 is one of the most abundant molecular chaperones. It modulates the stability and transport of a diverse set of critical factors, including regulatory, metabolic, organizational, and signaling proteins. There are two major isoforms: α and β. In humans, the Hsp90β isoform is constitutively expressed, whereas the Hsp90α isoform is expressed under stress conditions. The Hsp90 dimer acts in concert with other chaperones and is regulated by a number of co-chaperones/accessory proteins. Upregulation of Hsp90 is associated with tumor progression, invasion and formation of metastases, and development of drug resistance. Therefore Hsp90 has emerged as an important target for cancer treatment.

Immunogen

Amino acids 291-304 of human HSP90α and β

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Mouse

Isotype

IgG

Clone Number

CBP3889

Applications

WB; ICC; ELISA

Application Notes

WB (0.125-1.0 µg/mL)

Relevant Diseases

Brain Tumors; Alzheimer's Disease; Parkinson's Disease; Neurocutaneous Syndromes

Research Areas

Neuroinflammation; Neurodegeneration

Conjugation

Unconjugated

Product Properties

Form

Liquid

Formulation

PBS, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA.

Concentration

1.0 mg/mL

Purification

Affinity Chromatography

Purity

>95%, as determined by Coomassie stained SDS-PAGE.

Shipping

The product is shipped at 4°C. Upon receipt, store it immediately at the recommended temperature.

Storage

Upon initial thawing, apportion into working aliquots and store at -20°C. Avoid repeated freeze-thaw cycles to prevent denaturing the antibody.

Research Use Only

For research use only, not for diagnostic or therapeutic use.

Target

HSP90 alpha

Official Name

Hsp90

Full Name

Heat shock protein 90

Alternative Names

HATPase

Gene ID

3326(Human); 15516(Mouse); 301252(Rat)

Uniprot ID

P08238(Human); P11499(Mouse); P34058(Rat)

References

1. Barrott JJ, et al. 2013. FEBS J. 280:1381.
2. Gorska M, et al. 2012. Front. Biosci. (Landmark Ed) 17:2269.
3. Barginear MF, et al. 2008. Curr. Cancer Drug Targets. 8:522.
4. Arya R, et al. 2007. J. Biosci. 32:595.
5. Neckers L, et al. 2003. Curr. Opin. Oncol. 15:419.
6. Nemoto T, et al. 1997. J. Biol. Chem. 272: 26179.

Publications